投资评级 - 维持"谨慎推荐"评级 [4][6] 核心观点 - 2025年上半年营业收入40.50亿元同比下降26.1% 归母净利润5747.78万元同比下降89.58% 扣非归母净利润-1.70亿元同比盈转亏 [1] - 非经常性收益主要来自收回长期股权投资款增加非经常性损益2.13亿元 [1] - 25Q2营业收入18.58亿元同环比-42.2%/-15.3% 归母净利润2410.47万元同环比-94.2%/-27.8% 扣非归母净亏损-2.03亿元同环比盈转亏 [1] - 煤炭产销恢复但售价大幅下滑 尿素业务毛利率环比改善 己内酰胺业务亏损扩大 [2][3][4] - 预计2025-2027年归母净利润2.44/3.22/4.76亿元 对应EPS 0.17/0.22/0.32元/股 PE 42/32/21倍 [4][5] 财务表现 - 25H1煤炭产销量757.5/604.3万吨同比+7.3%/+4.9% 吨煤售价486.0元/吨同比-23.7% 吨煤销售成本337.8元/吨同比-4.7% 毛利率30.5%同比-13.9pct [2] - 25Q2煤炭产量389.2万吨同环比-1.2%/+5.7% 销量315.6万吨同环比-6.5%/+9.3% 吨煤售价438.0元/吨同环比-31.7%/-18.7% 吨煤销售成本343.9元/吨同环比-0.8%/+3.9% 毛利率21.5%同环比-24.4/-17.0pct [2] - 25H1尿素产销量40.6/39.4万吨同比-15.1%/-17.3% 综合售价1590.5元/吨同比-20.9% 销售成本1498.2元/吨同比-5.1% 毛利率5.8%同比-15.7pct [3] - 25Q2尿素产量21.0万吨同环比-18.4%/+6.9% 销量18.8万吨同环比-33.7%/-9.1% 综合售价1663.4元/吨同环比-16.8%/+9.1% 销售成本1476.5元/吨同环比-6.4%/-2.7% 毛利率11.2%同环比-9.8/+10.8pct [3] - 25H1己内酰胺业务同比增亏0.24亿元 25Q2同环比分别增亏0.29/0.12亿元 [3] 盈利预测 - 预计2025-2027年营业收入108.81/115.83/122.40亿元 增长率-7.0%/6.4%/5.7% [5][10] - 预计2025-2027年毛利率24.40%/26.53%/28.12% 净利润率2.24%/2.78%/3.89% [10] - 预计2025-2027年ROE 1.52%/1.97%/2.85% ROA 0.70%/0.91%/1.33% [10] - 预计2025-2027年每股收益0.17/0.22/0.32元 每股净资产10.91/11.08/11.33元 [5][10]